Tag:
BioDelivery Sciences
Latest Headlines
Latest Headlines
BDSI gets patent for anti-opioid film
BioDelivery Sciences International has secured a patent for its dissolvable opioid-dependence treatment, and the company is looking to get BEMA Buprenorphine on the market as soon as next year.
Endo grabs BDSI's drug film chronic pain treatment through global license
BioDelivery Sciences International ( $BDSI )'s dissolvable drug delivery film to treat chronic pain from inside the cheek is still under development and endured a recent clinical setback. But it's
BioDelivery Sciences shares spike on $180M pain drug deal with Endo Pharma
BioDelivery Sciences International ( $BDSI ) surged out of penny-stock territory this morning on news of its deal with Endo Pharmaceuticals ( $ENDP ) to partner on a version of the painkiller
MonoSol targets drug film rival's revenue in updated court complaint
Warren, NJ-based MonoSol Rx aims to get compensated after rival BioDelivery Sciences International ( $BDSI ) received $60 million in revenue from drug-delivery tech that is included in a
BioDelivery shares in meltdown after pain drug flunks PhIII placebo study
After the markets closed yesterday BioDelivery Sciences in Raleigh, NC put out a release detailing the late-stage failure of its pain drug, BEMA Buprenorphine. And despite the best efforts of the CEO
BDSI moves forward with anti-opioid drug, delivery method
Raleigh, NC-based BioDelivery Sciences International ( $BDSI ) is announcing positive preliminary results from its Phase I study of a high dose formulation of buprenorphine combined with naloxone
MonoSol Rx, BioDelivery Sciences trade accusations in lawsuit
Two drug-delivery companies are sparring with dueling press releases over a lawsuit alleging patent infringement and, in the latest development, false marking. In one corner there is New Jersey-based
Aveva plant restart rekindles BioDelivery, ProStrakan
Products from two drugmakers are going back into production following the facility restart of contract manufacturer Aveva Drug Delivery Systems. Aveva has notified the FDA that it plans to resume
BDSI, Meda, FDA talk about streamlining REMS for Onsolis
Raleigh, NC-based BioDelivery Sciences International has disclosed a July meeting with the FDA and Swedish pharmaceutical company Meda regarding the Onsolis cancer-pain treatment. The talks centered
BDSI gets $30M milestone
BioDelivery Sciences has pocketed a $30 million milestone payment from Meda as part of their licensing agreement for the commercialization of BEMA Fentanyl, a new pain patch for cancer patients. The
